热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Ultra-LEAF™ Purified anti-human CD3 Antibody
产品名称：
Ultra-LEAF™ Purified anti-human CD3 Antibody
产品类别：
抗体
产品编号：
317325
产品应用：
317325
[价格]
规格 价格 库存
100µg ￥ 99 1

产品详情

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 ?m filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/?g of the protein (<0.001 ng/?g of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF? (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF? solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 ?g per million cells in 100 ?l volume or 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  2. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  3. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  4. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  5. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  6. Hsiue EH, et al. 2021. Science. 371:. PubMed
  7. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  8. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  9. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  10. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  11. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  12. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  13. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  14. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  15. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  16. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  17. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  18. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  19. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  20. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  21. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  22. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  23. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  24. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  25. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  26. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  27. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  28. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  29. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  30. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  31. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  32. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  33. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  34. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  35. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  36. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  37. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  38. Sekine T, et al. 2020. Cell. 183:158. PubMed
  39. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  40. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  41. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  42. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  43. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  44. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  45. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  46. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  47. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  48. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  49. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  50. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  51. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  52. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  53. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  54. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  55. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  56. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  57. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  58. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  59. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  60. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_11147370 (BioLegend Cat. No. 317325) AB_11150592 (BioLegend Cat. No. 317326) AB_2571994 (BioLegend Cat. No. 317347) AB_2571995 (BioLegend Cat. No. 317348) AB_2749888 (BioLegend Cat. No. 317349) AB_2749889 (BioLegend Cat. No. 317350)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线